Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pixium Sees Way Forward For Its Vision-Restoring Implants In A Tough Market

Executive Summary

The company has just two quarters’ of cash remaining, but has also achieved major milestones towards the development and commercialization of its implant that hopes to restore vision in patients with age-related macular degeneration.

You may also be interested in...



LSI 2023: What Ophthalmology Start-Ups Pitched To Investors At Emerging Medtech Summit

Leaders of burgeoning ophthalmology companies pitched innovations for treating glaucoma, macular degeneration and corneal blindness to potential investors and partners at the LSI Emerging Medtech Summit in Dana Point, CA. Here’s what Medtech Insight heard and learned in on-site interviews with chief executives.

Investor Eye: Sofinnova Speaks On Deal Execution, Managing Expertise And what’s In Store For The Future

Times may look bleak for medtech investment. Public markets are down and VC is shyer than ever about spending money. Medtech Insight spoke to Antoine Papiernik of Sofinnova Partners to learn more about the path forward.

Money And Materials Will Allow Medtech To Restore Lost Neuro Functions

Medtech Insight spoke to the CEOs of Blackrock Neurotech and Pixium Vision to find out how their devices can restore lost neurological function and how devices that interface with the brain may shape the future of medicine.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel